QuarterHawk — Equity ResearchQuarterHawk — Equity Research

QuidelOrtho Corporation (QDEL)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
2

Do Nothing: fundamentalScore 2 and qualitativeScore 2 are below the required floor of 3; this strategy blocks a bullish entry despite adequate liquidity and a post-earnings rebound attempt.

Analysis as of 2026-08-16· more than 2 trading days ago

Company overview

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, blood/donor banks, and for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

Fundamental

weak
Fundamental2
Weak fundamentals

QuidelOrtho's fundamentals are challenged by ongoing losses, heavy leverage, and inconsistent DCF estimates.

QuidelOrtho has scale and mid-40% gross margins, but recent results remain loss-making with weak cash conversion and elevated leverage. SEC filings show adequate liquidity and covenant compliance, yet the latest earnings release reduced 2026 guidance and withdrew free-cash-flow guidance amid China pricing uncertainty and softer respiratory demand. This looks like a pressured turnaround setup rather than a stable, near-term fundamentals-driven opportunity.

Sentiment

weak
Sentiment2
Mixed sentiment

Media sentiment is mildly positive, but no clear catalysts or retail sentiment trends emerged.

Coverage over the last ~2 weeks turned net-negative around Q2 results and a full-year revenue outlook/guidance cut (announced), while the 30–90d baseline skewed positive on management and divestiture-related headlines—showing a clear short-term sentiment deterioration. Retail chatter is essentially absent and no regulator-confirmed investigations surfaced, but the post-earnings reset keeps the near-term setup cautious (moderate red-flag cap applied for sharp sentiment deterioration).

Technical

weak
Technical2
Mixed rebound

The stock has reclaimed some moving averages, but lacks momentum confirmation for a bullish trend.

QDEL is trying to rebound from the 2026-08-07 earnings-gap washout, but the stock still closed below daily VWAP 14.52, EMA9 14.99, EMA21 15.62, SMA20 15.95, SMA50 15.75 and SMA200 20.18. RSI14 41.69, MACD -0.48/-0.17 and ADX14 20.26 keep the read in bounce-only territory rather than a confirmed short-term uptrend.

You’re looking at 2026-08-16 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.